Skip to Content

Osmolex ER Approval History

FDA Approved: Yes (First approved February 20, 2018)
Brand name: Osmolex ER
Generic name: amantadine hydrochloride
Dosage form: Extended-Release Tablets
Company: Osmotica Pharmaceutical US LLC
Treatment for: Parkinson's Disease, Extrapyramidal Reaction

Osmolex ER (amantadine hydrochloride) is a proprietary formulation of immediate release and extended release amantadine for the once-a-day treatment of Parkinson’s disease and drug-induced extrapyramidal reactions.

Development History and FDA Approval Process for Osmolex ER

DateArticle
Feb 19, 2018Approval FDA Approves Osmolex ER (amantadine) for the treatment of Parkinson’s Disease and Drug-Induced Extrapyramidal Reactions
Jul 22, 2015Osmotica Announces OS-320 (Osmolex ER), Has Been Awarded Orphan Drug Status by the FDA

Further information

Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.

Hide